AllSight
Companies · DFTX · Medicinal Chemicals & Botanical Products

Definium Therapeutics, Inc. (DFTX)

Definium Therapeutics, Inc. (DFTX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Definium Therapeutics, Inc. (DFTX) stock — financials & valuation

Key numbers for Definium Therapeutics, Inc. (DFTX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 52/100 — a percentile rank of Definium Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$5.1B
EV / EBITDA-19.5×
Return on equity-38.5%
Debt / equity0.0×
Dividend yield0.0%

Independent of the events above — derived from Definium Therapeutics, Inc.’s own financial statements and shown as context, never as advice.

Sep 14, 2026Above the bar
Definium’s Panorama clears Phase 3 GAD hurdle, but eight-hour monitoring remains
Sep 8, 2026Breakthrough designation
Definium wins second FDA breakthrough designation, but the efficacy news was already known
Aug 12, 2026Above the bar
The real surprise: one-dose anxiety relief with an 8-hour clinic session
Aug 6, 2026
Strong Emerge efficacy confirmed; quarterly update adds limited new upside
Related companies in Medicinal Chemicals & Botanical Products
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact